Community Health Media shared a post on X:
“At ASCO25, first results from DESTINY-Breast09 (DB09) showed that T-DXd + pertuzumab outperformed standard THP in 1L HER2+ MBC.
Dr. Jason A. Mouabbi and Paolo Tarantino discuss how this regimen could reshape frontline treatment in HER2+ metastatic breast cancer.”
Paolo Tarantino, 2025 Yvonne ‘Top Voice’ Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared this post, adding:
“Months before the DB09 presentation, I had a fun discussion with Jason A. Mouabbi on how to implement the 1L T-DXd/P regimen in clinical practice.
All thought are still valid in this post-DB09 era. In which breast oncs will need, more than ever, to tailor, adapt, be artisans of oncology.”
Proceed to the video attached to the post.
More posts featuring Breast cancer.